JP6952685B2 - 線維症の治療において使用するためのエンドスタチン断片およびバリアント - Google Patents

線維症の治療において使用するためのエンドスタチン断片およびバリアント Download PDF

Info

Publication number
JP6952685B2
JP6952685B2 JP2018515195A JP2018515195A JP6952685B2 JP 6952685 B2 JP6952685 B2 JP 6952685B2 JP 2018515195 A JP2018515195 A JP 2018515195A JP 2018515195 A JP2018515195 A JP 2018515195A JP 6952685 B2 JP6952685 B2 JP 6952685B2
Authority
JP
Japan
Prior art keywords
seq
endostatin
fibrosis
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018515195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524019A (ja
JP2018524019A5 (enExample
Inventor
フェガリ−ボストウィック，キャロル
ライアン，テレンス・イー
パジェット，ハル・エス
マギー，マシュー
ホルツ，アール・バリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research and Development
Novici Biotech LLC
Ibio Inc
Original Assignee
MUSC Foundation for Research and Development
Novici Biotech LLC
Ibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSC Foundation for Research and Development, Novici Biotech LLC, Ibio Inc filed Critical MUSC Foundation for Research and Development
Publication of JP2018524019A publication Critical patent/JP2018524019A/ja
Publication of JP2018524019A5 publication Critical patent/JP2018524019A5/ja
Priority to JP2021158128A priority Critical patent/JP7404320B2/ja
Application granted granted Critical
Publication of JP6952685B2 publication Critical patent/JP6952685B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018515195A 2015-06-05 2016-06-03 線維症の治療において使用するためのエンドスタチン断片およびバリアント Expired - Fee Related JP6952685B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021158128A JP7404320B2 (ja) 2015-06-05 2021-09-28 線維症の治療において使用するためのエンドスタチン断片およびバリアント

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562171889P 2015-06-05 2015-06-05
US62/171,889 2015-06-05
US201562257607P 2015-11-19 2015-11-19
US62/257,607 2015-11-19
PCT/US2016/035858 WO2016197018A1 (en) 2015-06-05 2016-06-03 Endostatin fragments and variants for use in treating fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021158128A Division JP7404320B2 (ja) 2015-06-05 2021-09-28 線維症の治療において使用するためのエンドスタチン断片およびバリアント

Publications (3)

Publication Number Publication Date
JP2018524019A JP2018524019A (ja) 2018-08-30
JP2018524019A5 JP2018524019A5 (enExample) 2019-07-04
JP6952685B2 true JP6952685B2 (ja) 2021-10-20

Family

ID=56236074

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018515195A Expired - Fee Related JP6952685B2 (ja) 2015-06-05 2016-06-03 線維症の治療において使用するためのエンドスタチン断片およびバリアント
JP2021158128A Active JP7404320B2 (ja) 2015-06-05 2021-09-28 線維症の治療において使用するためのエンドスタチン断片およびバリアント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021158128A Active JP7404320B2 (ja) 2015-06-05 2021-09-28 線維症の治療において使用するためのエンドスタチン断片およびバリアント

Country Status (10)

Country Link
US (2) US10844392B2 (enExample)
EP (1) EP3303383A1 (enExample)
JP (2) JP6952685B2 (enExample)
KR (1) KR20180033499A (enExample)
CN (2) CN107849117B (enExample)
AU (2) AU2016270428B2 (enExample)
BR (1) BR112017026209A2 (enExample)
CA (1) CA2988299C (enExample)
WO (1) WO2016197018A1 (enExample)
ZA (1) ZA201708223B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022002527A (ja) * 2015-06-05 2022-01-11 アイバイオ・インコーポレイテッドIbio, Inc. 線維症の治療において使用するためのエンドスタチン断片およびバリアント

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210058902A (ko) * 2018-09-14 2021-05-24 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 sPD-1 변이체-FC 융합 단백질
EP3996736A4 (en) * 2019-07-10 2023-05-24 Musc Foundation for Research Development ENDOSTATIN PEPTIDES FOR THE TREATMENT OF TUMOR, FIBROSIS AND ACUTE LUNG INJURY
US12454551B2 (en) * 2019-07-31 2025-10-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Peptides as inhibitors of fibrotic matrix accumulation
JP7493945B2 (ja) * 2020-01-28 2024-06-03 ポーラ化成工業株式会社 培養組織の観察方法、培養方法、評価方法及び培養器具
US20230265407A1 (en) * 2020-07-02 2023-08-24 Northwestern University Human recombinant ace2-fc mutants that decouple anti-sars-cov-2 activity from cardiovascular effects
CA3195315A1 (en) * 2020-11-30 2022-06-02 Fred Hutchinson Cancer Center Compositions and methods for selective depletion of target molecules
WO2023039399A2 (en) * 2021-09-07 2023-03-16 Musc Foundation For Research Development Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US750375A (en) 1904-01-26 Potato-digger
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
ATE179862T1 (de) 1989-07-06 1999-05-15 Univ California Rezeptoren für fibroblasten-wachstumsfaktoren
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5756671A (en) 1994-06-02 1998-05-26 Mitotix, Inc. CDC37 cell-cycle regulatory protein, and uses related thereto
US6080560A (en) * 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6165460A (en) 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
DE19535939A1 (de) 1995-09-27 1997-04-03 Agfa Gevaert Ag Fotografisches Material
KR20010015868A (ko) 1997-12-08 2001-02-26 베쓰 이스라엘 디코니스 메디칼 센터 피치아 효모 발현계를 사용하여 항혈관형성 단백질인엔도스타틴, 안지오스타틴 또는 레스틴을 생성시키는 방법
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
KR20010052566A (ko) * 1998-06-03 2001-06-25 윌리엄 뉴 엔도스타틴 단백질을 포함하는 단백질 올리고머 조성물 및이의 사용방법
US6399075B1 (en) 1998-07-02 2002-06-04 President And Fellows Of Harvard College Compositions and methods for treating Papillomavirus-infected cells
WO2000046350A1 (en) 1999-02-05 2000-08-10 Thomas Jefferson University Production of biomedical peptides and proteins in plants using transcomplementation systems
AU3224700A (en) 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
AU2004209660A1 (en) 2003-02-03 2004-08-19 Fraunhofer Usa, Inc. System for expression of genes in plants
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
JP2010531666A (ja) * 2007-06-26 2010-09-30 ユニバーシティ オブ マイアミ 抗体−エンドスタチン融合タンパク質及びそのバリアント
WO2011050311A1 (en) 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis
WO2013013085A2 (en) * 2011-07-19 2013-01-24 Thrasos Innovation, Inc. Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
CA2988299C (en) 2015-06-05 2023-10-31 Ibio, Inc. Endostatin fragments and variants for use in treating fibrosis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022002527A (ja) * 2015-06-05 2022-01-11 アイバイオ・インコーポレイテッドIbio, Inc. 線維症の治療において使用するためのエンドスタチン断片およびバリアント
JP7404320B2 (ja) 2015-06-05 2023-12-25 アイバイオ・インコーポレイテッド 線維症の治療において使用するためのエンドスタチン断片およびバリアント
US11912755B2 (en) 2015-06-05 2024-02-27 Bio, Inc. Endostatin fragments and variants for use in treating fibrosis

Also Published As

Publication number Publication date
JP2022002527A (ja) 2022-01-11
US11912755B2 (en) 2024-02-27
CN115925878A (zh) 2023-04-07
JP7404320B2 (ja) 2023-12-25
EP3303383A1 (en) 2018-04-11
CN107849117A (zh) 2018-03-27
BR112017026209A2 (pt) 2018-11-27
ZA201708223B (en) 2018-11-28
AU2016270428B2 (en) 2020-11-26
US20180179263A1 (en) 2018-06-28
CA2988299C (en) 2023-10-31
CA2988299A1 (en) 2016-12-08
KR20180033499A (ko) 2018-04-03
WO2016197018A8 (en) 2017-07-13
AU2021200765B2 (en) 2023-04-13
WO2016197018A9 (en) 2017-01-19
AU2021200765A1 (en) 2021-03-04
WO2016197018A1 (en) 2016-12-08
US10844392B2 (en) 2020-11-24
US20210108221A1 (en) 2021-04-15
JP2018524019A (ja) 2018-08-30
AU2016270428A1 (en) 2018-01-25
CN107849117B (zh) 2022-08-26

Similar Documents

Publication Publication Date Title
JP7404320B2 (ja) 線維症の治療において使用するためのエンドスタチン断片およびバリアント
US10709769B2 (en) Use of endostatin peptides for the treatment of fibrosis
KR20140128971A (ko) 세포-투과성 펩티드
WO2009032477A2 (en) Vegfr-1/nrp-1 targeting peptides
EP3957323A1 (en) Porcine epidemic diarrhea (ped) virus vaccine composition and preparation method therefor
CN114846020B (zh) 逆向-反转肽
CN114573686A (zh) 含有二硫键且具有抑制丝氨酸蛋白酶活性的多肽及其应用
KR102077772B1 (ko) 광견병 예방용 백신 조성물 및 이의 제조 방법
PT1616007E (pt) Proteínas inibidoras de uma protease e uso das mesmas
CN114867527A (zh) 大环肽
US8367801B2 (en) Proteinaceous compounds
CN109476702B (zh) 肽及其用途
HK40107416A (zh) 抗cd25抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200331

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210928

R150 Certificate of patent or registration of utility model

Ref document number: 6952685

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees